Related Experiment Video
Updated: May 7, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs]
Haras Mhmud1,2, Odette A M Tigchelaar-Besling3, Jeroen P Vermeulen4
1Radboudumc, afd. Oogheelkunde, Nijmegen.
Objective:
To study the long-term outcomes of anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) in the Netherlands, where off-label bevacizumab is used as the first choice, compared to countries that typically use ranibizumab or aflibercept.
Design:
Prospective real-world observational study.
Methods:
A total of 1,617 Dutch eyes were compared with 8,667 eyes from a reference group derived from 13 socio-economically comparable countries. The primary outcome was the mean visual acuity (VA) measured at annual intervals up to 60 months. Secondary outcomes included injection frequency and the rate of switching to an alternative injection type.
Results:
Dutch eyes exhibited higher VA, received two additional injections annually and switched to alternative treatments more frequently (65.2% vs. 50.1%) and sooner (14.6 months vs. 17.9 months).
Conclusion:
Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.
More Related Videos
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Diabetic Retinopathy